Skip to main content

Advertisement

SpringerLink
Log in

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical research model capable of predicting the sensitivities of anti-tumor drugs.

Methods

Twenty-eight patients with HCC were selected to use the MiniPDX model to screen the most sensitive anti-tumor drugs from five groups of drug regimens for preventive treatment after partial hepatectomy, and another 42 patients with HCC were selected to be treated with Sorafenib during the same period as the control group. The tumor-free survival rate and overall survival rate were analyzed and compared between these two groups. The relationship between drug sensitivity and biomarkers related to HCC was also analyzed.

Results

Kaplan–Meier survival curve analysis showed that the tumor-free survival (DFS) of patients in the MiniPDX group was significantly longer than that in the control group (median DFS: 25.8 months vs. 18.2 months, P = 0.022, HR 2.19, 95% CI 1.17–4.12). The overall survival (OS) of the patients in the MiniPDX group was also longer than that in the control group (median OS: 29.4 months vs. 23.8 months, P = 0.039, HR 2.37, 95% CI 1.12–5.00). The longest follow-up period was 36 months. The relationship analyzed between the efficacy of the five drugs (Regorafenib, Regorafenib, Lenvatinib, Gemcitabine, 5-FU + Oxaliplatin) and AFP, Ki-67, VEGFR, FGFR, P53, and Nrf2 showed different correlations.

Conclusion

The use of the MiniPDX model to select drugs to guide anti-tumor treatment after partial hepatectomy could effectively prolong the survival of patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: Cancer J Clin 68(6):394–424

    Google Scholar 

  2. Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma [J]. Gastroenterology 156(2):477-491 e471

    PubMed  Google Scholar 

  3. Hernandez MC, Bergquist JR, Leiting JL et al (2019) Patient-derived xenografts can be reliably generated from patient clinical biopsy specimens [J]. J Gastrointest Surg: Off J Soc Surg Aliment Tract 23(4):818–824

    Google Scholar 

  4. Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: new avatars of personalized cancer therapy [J]. Cancer Lett 344(1):1–12

    CAS  PubMed  Google Scholar 

  5. Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development [J]. Nat Rev Clin Oncol 9(6):338–350

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Huynh H, Ong R, Soo KC (2012) Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma [J]. Angiogenesis 15(1):59–70

    CAS  PubMed  Google Scholar 

  7. Zhang F, Wang W, Long Y et al (2018) Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response [J]. Cancer Commun 38(1):60

    Google Scholar 

  8. Zhan M, Yang RM, Wang H et al (2018) Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients [J]. Cancer Commun 38(1):48

    Google Scholar 

  9. Cwinn M, Molinari M (2016) Regional variations in treatment modalities for hepatocellular carcinoma in Canada [J]. Hpb 18:e196–e197

    Google Scholar 

  10. Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence-based medicine [J]. World J Gastroenterol 20(15):4115–4127

    PubMed  PubMed Central  Google Scholar 

  11. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma [J]. Hepatology 48(4):1312–1327

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the sharp trial [J]. Expert Rev Anticancer Ther 9(6):739–745

    CAS  PubMed  Google Scholar 

  13. Khandelwal G, Girotti MR, Smowton C et al (2017) Next-generation sequencing analysis and algorithms for pdx and cdx models [J]. Mol Cancer Res: MCR 15(8):1012–1016

    CAS  PubMed  Google Scholar 

  14. Koga Y, Ochiai A (2019) Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors [J]. Cells 8(5):418

    CAS  PubMed Central  Google Scholar 

  15. Zhao P, Chen H, Wen D et al (2018) Personalized treatment based on mini patient-derived xenografts and wes/rna sequencing in a patient with metastatic duodenal adenocarcinoma [J]. Cancer Commun 38(1):54

    Google Scholar 

  16. Cheng A-L, Finn RS, Qin S et al (2017) Phase iii trial of lenvatinib (len) vs sorafenib (sor) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uhcc) [J]. J Clin Oncol 35(15_suppl):4001–4001

    Google Scholar 

  17. Llovet J, Cheng A, Qin S et al (2019) 6519 efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (hcc): collective results from the phase III sorafenib HCC assessment randomized protocol (sharp) and Asia-Pacific (AP) trials [J]. Eur J Cancer Suppl 7(2):367

    Google Scholar 

  18. Llovet JM (2008) Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med 359(23):2498 (author reply 2498–2499)

    CAS  Google Scholar 

  19. Ikeda M, Mitsunaga S, Ohno I et al (2015) Systemic chemotherapy for advanced hepatocellular carcinoma: Past, present, and future [J]. Diseases 3(4):360–381

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Kudo M, Trevisani F, Abou-Alfa GK et al (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment [J]. Liver cancer 6(1):16–26

    PubMed  PubMed Central  Google Scholar 

  21. Qin S, Cheng Y, Liang J et al (2014) Efficacy and safety of the folfox4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the each study [J]. Oncologist 19(11):1169–1178

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Ikeda M, Morizane C, Ueno M et al (2018) Chemotherapy for hepatocellular carcinoma: current status and future perspectives [J]. Jpn J Clin Oncol 48(2):103–114

    PubMed  Google Scholar 

  23. Raghunath A, Sundarraj K, Arfuso F et al (2018) Dysregulation of nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance [J]. Cancers 10(12):481

    CAS  PubMed Central  Google Scholar 

  24. He C, Li L, Guan X et al (2017) Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy [J]. Chemotherapy 62(1):43–53

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We appreciate Dr. Wen Danyi (LIDE Biotech Inc.) for providing technical support on MiniPDX models.

Funding

This work was supported by the Foundation of Tianjin Science and technology plan project (19ZXDBSY00010), Key projects of Tianjin Health Industry (16KG108).

Author information

Authors and Affiliations

  1. Medical School of Nankai University, No. 94, Weijin Road, Nankai District, Tianjin, China

    Long Yang

  2. Department of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, No. 24 Fukang Road, Nankai District, Tianjin, China

    Long Yang, Zheyue Yuan, Yamin Zhang, Zilin Cui, Yang Li, Jiancun Hou, Xiaolong Liu, Zirong Liu, Rui Shi, Qing Tian, Jian Wang & Lianjiang Wang

Authors
  1. Long Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zheyue Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yamin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zilin Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiancun Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaolong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zirong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rui Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qing Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lianjiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yamin Zhang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, L., Yuan, Z., Zhang, Y. et al. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 87, 125–134 (2021). https://doi.org/10.1007/s00280-020-04182-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-020-04182-1

Keywords

Search

Navigation